More specifically, the use of a murine MM model enabled them to evaluate the in vivo effects of miR-137 overexpression upon bortezomib treatment, showing smaller tumor volumes and an increased sensitivity to treatment due to downregulation of the AURKA/p53/ATM/Chk2 pathway involved in apoptosis and CIN. The gene discussed is TP53; the disease is Miyoshi myopathy.